Biology and Treatment of Acute Lymphoblastic Leukemia

被引：34

作者：

Pieters, Rob ^{[1
]}

Carroll, William L. ^{[2
]}

机构：

[1] Erasmus MC Sophia Childrens Hosp, Dept Pediat Oncol & Hematol, NL-3015 GJ Rotterdam, Netherlands

[2] NYU Med Ctr, Div Pediat Hematol Oncol, New York, NY 10016 USA

来源：

HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA | 2010年 / 24卷 / 01期

关键词：

Acute lymphoblastic leukemia; Children; Adolescents; Chemotherapy; Genomics; Targeted therapy; CHILDRENS-CANCER-GROUP; VITRO DRUG-RESISTANCE; ESCHERICHIA-COLI-ASPARAGINASE; STEM-CELL TRANSPLANTATION; DOSE L-ASPARAGINASE; EVENT-FREE SURVIVAL; TERM FOLLOW-UP; IN-VITRO; STANDARD-RISK; DELAYED INTENSIFICATION;

D O I：

10.1016/j.hoc.2009.11.014

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Acute lymphoblastic leukemia (ALL), the most common type of cancer in children, is a heterogeneous disease in which many genetic lesions result in the development of multiple biologic subtypes. Today, with intensive multiagent chemotherapy, most children who have ALL are cured. The many national or institutional ALL therapy protocols in use tend to stratify patients in a multitude of different ways to tailor treatment to the rate of relapse. This article discusses the factors used in risk stratification and the treatment of pediatric ALL.

引用

页码：1 / +

页数：19

共 103 条

[1] Intensive high-dose asparaginase consolidation improves survival for pediatric patients with T cell acute lymphoblastic leukemia and advanced stage lymphoblastic lymphoma: a Pediatric Oncology Group study [J].

Amylon, MD ;

Shuster, J ;

Pullen, J ;

Berard, C ;

Link, MP ;

Wharam, M ;

Katz, J ;

Yu, A ;

Laver, J ;

Ravindranath, Y ;

Kurtzberg, J ;

Desai, S ;

Camitta, B ;

Murphy, SB .

LEUKEMIA, 1999, 13 (03) :335-342

[2] Lack of asparagine depletion in the cerebrospinal fluid after one intravenous dose of PEG-asparaginase: a window study at initial diagnosis of childhood ALL [J].

Appel, JM ;

Pinheiro, JPV ;

den Boer, ML ;

Lanvers, C ;

Reniers, NCM ;

Boos, J ;

Pieters, R .

LEUKEMIA, 2003, 17 (11) :2254-2256

[3] Outcome of treatment in children with philadelphia chromosome-positive acute lymphoblastic leukemia [J].

Aricò, M ;

Valsecchi, MG ;

Camitta, B ;

Schrappe, M ;

Chessells, J ;

Baruchel, A ;

Gaynon, P ;

Silverman, L ;

Janka-Schaub, G ;

Kamps, W ;

Pui, CH ;

Masera, G .

NEW ENGLAND JOURNAL OF MEDICINE, 2000, 342 (14) :998-1006

[4] The Seventh International Childhood Acute Lymphoblastic Leukemia Workshop Report: Palermo, Italy, January 29–30, 2005 [J].

M Aricó ;

A Baruchel ;

Y Bertrand ;

A Biondi ;

V Conter ;

T Eden ;

H Gadner ;

P Gaynon ;

K Horibe ;

S P Hunger ;

G Janka-Schaub ;

G Masera ;

J Nachman ;

R Pieters ;

M Schrappe ;

K Schmiegelow ;

M G Valsecchi ;

C-H Pui .

Leukemia, 2005, 19 (7) :1145-1152

[5] Inhibition of FLT3 in MLL: Validation of a therapeutic target identified by gene expression based classification [J].

Armstrong, SA ;

Kung, AL ;

Mabon, ME ;

Silverman, LB ;

Stam, RW ;

Den Boer, ML ;

Pieters, R ;

Kersey, JH ;

Sallan, SE ;

Fletcher, JA ;

Golub, TR ;

Griffin, JD ;

Korsmeyer, SJ .

CANCER CELL, 2003, 3 (02) :173-183

[6] MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia [J].

Armstrong, SA ;

Staunton, JE ;

Silverman, LB ;

Pieters, R ;

de Boer, ML ;

Minden, MD ;

Sallan, SE ;

Lander, ES ;

Golub, TR ;

Korsmeyer, SJ .

NATURE GENETICS, 2002, 30 (01) :41-47

[7] A randomized comparison of native Escherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia:: a Children's Cancer Group study [J].

Avramis, VI ;

Sencer, S ;

Periclou, AP ;

Sather, H ;

Bostrom, BC ;

Cohen, LJ ;

Ettinger, AG ;

Ettinger, LJ ;

Franklin, J ;

Gaynon, PS ;

Hilden, JM ;

Lange, B ;

Majlessipour, F ;

Mathew, P ;

Needle, M ;

Neglia, J ;

Reaman, G ;

Holcenberg, JS .

BLOOD, 2002, 99 (06) :1986-1994

[8] Chemotherapy versus allogeneic transplantation for very-high-risk childhood acute lymphoblastic leukaemia in first complete remission: comparison by genetic randomisation in an international prospective study [J].

Balduzzi, A ;

Valsecchi, MG ;

Uderzo, C ;

De Lorenzo, P ;

Klingebiel, T ;

Peters, C ;

Stary, J ;

Felice, MS ;

Magyarosy, E ;

Conter, V ;

Reiter, A ;

Messina, C ;

Gadner, H ;

Schroppe, M .

LANCET, 2005, 366 (9486) :635-642

[9] Lymphoblast biology and outcome among children with Down syndrome and ALL treated on CCG-1952 [J].

Bassal, M ;

La, MK ;

Whitlock, JA ;

Sather, HN ;

Heerema, NA ;

Gaynon, PS ;

Stork, LC .

PEDIATRIC BLOOD & CANCER, 2005, 44 (01) :21-28

[10] Phase II study of nelarabine (compound 506U78) in children and young adults with refractory T-Cell malignancies: A report from the children's oncology group [J].

Berg, SL ;

Blaney, SM ;

Devidas, M ;

Lampkin, TA ;

Murgo, A ;

Bernstein, M ;

Billett, A ;

Kurtzberg, J ;

Reaman, G ;

Gaynon, P ;

Whitlock, J ;

Krailo, M ;

Harris, MB .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (15) :3376-3382

← 1 2 3 4 5 6 7 8 9 10 →